Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.

Journal of cardiovascular pharmacology - 1 Apr 2018

Verbrugghe Peter, Verhoeven Jelle, Clijsters Marnick, Vervoort Dominique, Schepens Jarne, Meuris Bart, Herijgers Paul

Abstract excerpt

INTRODUCTION: Available evidence suggests that the renin-angiotensin-aldosterone (RAA) system is a good target for medical intervention on aortic root dilatation in Marfan syndrome (MFS). The effect of Compound 21 (C21), a nonpeptide angiotensin II type 2 receptor agonist, on aneurysm progression was tested. METHODS: Mice with a mutation in fibrillin-1 (Fbn1) and wild-type mice were treated with vehicle,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Aortic Aneurysm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dilatation, Pathologic

Share to Fibrillin-1

Share to Losartan

Share to Marfan Syndrome

Share to Receptor, Angiotensin, Type 2

Share to Thiophenes

Source

Open in PubMed Open full text

Identifiers

PMID: 29300219
DOI: 10.1097/FJC.0000000000000560
PMCID: PMC5902135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.PMID 29300219Read ↗

[Novel pharmacological strategies for aortic dilation in Marfan syndrome: from mouse models to human patients].Semantic proximity Read ↗

Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Aortic Aneurysm Formation in Marfan SyndromeSemantic proximity Read ↗

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.Semantic proximity Read ↗

Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions.Semantic proximity Read ↗

Inhibition of Angiotensin II Dependent AT1a Receptor Stimulation Attenuates Thoracic Aortic Pathology in Fibrillin-1 <sup>C1041G/+</sup> MiceSemantic proximity Read ↗

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.Semantic proximity Read ↗

Deletion of AT1a (Angiotensin II Type 1a) Receptor or Inhibition of Angiotensinogen Synthesis Attenuates Thoracic Aortopathies in Fibrillin1C1041G/+ Mice.Semantic proximity Read ↗

Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.Semantic proximity Read ↗

17 β-estradiol impedes aortic root dilation and rupture in male Marfan miceSemantic proximity Read ↗

Growth of the aortic root in children and young adults with Marfan syndrome.Semantic proximity Read ↗

Beneficial Outcome of Losartan Therapy Depends on Type of <i>FBN1</i> Mutation in Marfan SyndromeSemantic proximity Read ↗

Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.